|Bid||65.00 x 1100|
|Ask||68.50 x 4000|
|Day's Range||66.42 - 68.86|
|52 Week Range||60.23 - 118.32|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
As discussed earlier, Sage Therapeutics (SAGE) is focused on the development of products for the treatment of life-threatening central nervous system (or CNS) disorders. The products under development include SAGE-718 and SAGE-904.
Biotechnology company Shire (SHPG) reported a 4.6% YoY (year-over-year) rise in revenue to ~$3.9 billion in the second quarter compared to $3.7 billion in the second quarter of 2017.
Incyte Corporation (NASDAQ:INCY), a large-cap worth US$14.42b, comes to mind for investors seeking a strong and reliable stock investment. Most investors favour these big stocks due to their strong balanceRead More...
Pipeline updates and collaborating agreement comprise some of the key developments in the biotech sector this week.
Incyte (INCY) inks an agreement with Foundation Medicine for the development of companion diagnostics (CDx) for Incy's selective FGFR Inhibitor, pemigatinib.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Stocks that hit 52-week highs Sept. 7.) Amgen, Inc. (NASDAQ: AMGN )/p BioSpecifics Technologies ...
After recording stellar gains of 4.3 percent in the week ended Aug. 31 to close the month in the green, the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) saw a moderation in momentum in the holiday-shortened ...
The following stocks are currently in the midst of strong trendsaccording to VantagePoint , an AI charting platform that uses intermarket analysis and artificial intelligence to predict future price action ...
Biotech stocks are hot and have rallied by 13% as measured by the iShares Nasdaq Biotechnology ETF ( IBB) since late May. The recent increase has helped the ETF rise by 14% for the year, beating the S&P 500's gain of 9%. Companies like Celgene Corp. ( CELG), Regeneron Pharmaceuticals Inc. ( REGN) and Incyte Corp. ( INCY) may rise by 10% or more in the coming weeks based on the technical charts, leading the charge higher. The Nasdaq Biotech ETF is breaking out as it rises above a long-term downtrend that has been in place since the summer of 2015.
Wall Street analysts expect Incyte (INCY) to report a 17.8% YoY (year-over-year) rise in sales to $1.81 billion in 2018 compared to $1.54 billion in 2017. Incyte is expected to report net adjusted income of $245.1 million in 2018 compared to net adjusted income of -$313.1 million in 2017. Incyte’s stock price has fallen nearly 42.4% over the last 12 months and nearly 26.5% year-to-date in 2018.
Incyte’s (INCY) product portfolio includes the targeted therapies and immunotherapies for the treatment of oncology and non-oncology diseases.
Momelotinib once looked like a promising treatment for a bone marrow disorder, but after mixed results in late-stage clinical trials, Gilead shelved it. Now it's sold the drug to a Canadian company.
Incyte (INCY) reported revenue of $521.5 million in the second quarter, a 59.7% rise YoY (year-over-year) compared to $326.4 million in the second quarter of 2017.
Incyte (INCY), a biopharmaceutical company, is focused on the discovery, development, and commercialization of various products to cater to unmet medical needs in oncology and the treatment of other diseases.
Incyte Corporation (NASDAQ: INCY) took it on the chin in April, as the company announced that its Phase 3 study for an experimental combo with Merk & Co., Inc. (NYSE: MRK) had failed to reach its primary endpoint.
Exelixis (EXEL) generated net revenues of $186.1 million in the second quarter of 2018 compared to $99 million in the second quarter of 2017. In the first half of 2018, Exelixis reported revenues of $399.8 million compared to $179.9 million in the first half of 2017. In the first half of 2018, Exelixis generated revenues of $280.1 million, reflecting ~92% YoY (year-over-year) growth.
Ionis Pharmaceuticals (IONS), a leading RNA-targeted therapeutics developing company, aims to develop best-in-class drugs for life-threatening diseases. Ionis commercializes the approved products in collaboration with other pharmaceuticals companies. Ionis reported revenues of $118 million in Q2 2018, a 5% increase in year-over-year (or YoY) revenues as compared to the second quarter of 2017.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting INCY. Over the last month, growth of ETFs holding INCY is favorable, with net inflows of $19.82 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing.
Of course, it's difficult to predict which technologies will change our world and how long their influence will last. On top of that, it's often a challenge for investors to identify investable opportunities associated with these groundbreaking technologies. The Morningstar Exponential Technologies Index focuses on finding high-growth companies that are in the early stages of developing technologies that are expected to have a broad impact on society and transform how we live and work.